1. Azithromycin for the Secondary Prevention of Coronary Events J. Thomas Grayston, M.D., Richard A. Kronmal, Ph.D., Lisa A. Jackson, M.D., Alfred F. Parisi, M.D., Joseph B. Muhlestein, M.D., Jerome D. Cohen, M.D., William J. Rogers, M.D., John R. Crouse, M.D., Sandra L. Borrowdale, M.S., Eleanor Schron, M.S., Charles Knirsch, M.D. and the ACES Investigators N Engl J Med Volume 352;16:1637-1645 April 21, 2005

2. Study Overview Since Chlamydia pneumoniae is believed to be involved in the pathogenesis of coronary artery disease, this study investigated whether antibiotic therapy with azithromycin to eliminate C pneumoniae would reduce the risk of coronary events There was no beneficial effect associated with azithromycin This study, along with that reported by Cannon et al in this issue of the Journal, does not support the idea that C pneumoniae has a significant pathogenic role in coronary artery disease

3. Baseline Characteristics of Participants in ACES, According to Study Group Grayston, J. et al. N Engl J Med 2005;352:1637-1645

4. Kaplan-Meier Curves Representing the Cumulative Rate of the Primary End Point, According to Study Group Grayston, J. et al. N Engl J Med 2005;352:1637-1645

5. Proportion of Participants with Each Event Contributing to the Primary End Point, According to Event and Study Group Grayston, J. et al. N Engl J Med 2005;352:1637-1645

6. Proportion of Participants with Primary or Secondary End-Point Events, According to Type of Event and Study Group Grayston, J. et al. N Engl J Med 2005;352:1637-1645

7. Risk of the Primary End Point Associated with Azithromycin Treatment, Stratified According to Baseline Characteristics Considered to Be Coronary Risk Factors Grayston, J. et al. N Engl J Med 2005;352:1637-1645

8. Symptoms Reported by Participants during the One-Year Treatment Period Grayston, J. et al. N Engl J Med 2005;352:1637-1645

9. Conclusions A one-year course of weekly azithromycin did not alter the risk of cardiac events among patients with stable coronary artery disease